Hamburg, January 8, 2020 – Beiersdorf and Insilico Medicine, an artificial intelligence company developing end to end drug discovery pipelines, announced today that they are entering a collaboration to jointly discover novel, safe bioactive ingredients for a specific skin indication at an unparalleled pace, that will serve as the basis for developing appropriate skincare products. "As part of our Open Innovation culture, we are always looking for new technologies and partners with strengths that complement ours. We are delighted to now be working with Insilico Medicine as a veritable expert when it comes to artificial intelligence. We are able to evaluate new active ingredients significantly more quickly and more efficiently by simulating biological effects in silico. This enables us to cater even better to the consumers' as yet unmet skincare needs," explains Dr. May Shana'a, Senior Corporate Vice President, Research and Development, at Beiersdorf.